Primary Hyperparathyroidism in Pregnancy: A Case Report

Cristina Zanardinia, Rossana Orabonaa, b, f, Sonia Zatti,a, Carlo Cappelli,c, Claudio Casella,d, Carla Baronchelli,e, Enrico Sartori,a, b

Abstract

Primary hyperparathyroidism (PHP) is the third most common endocrine disorder. We report the case of a 28-year-old woman who experienced general weakness, hyperemesis gravidarum and hypercalcemia at 11 weeks of gestation. Corresponding to hypercalcemia, we found inappropriately elevated parathyroid hormone levels. Through neck computed tomography a solitary adenoma of the parathyroid gland, measuring 6 × 2.9 × 11 mm has been documented. An ultrasound-guided fine needle aspiration from the mass confirmed the suspicious of a benign tumor. Left superior parathyroidectomy resulted in immediate and permanent resolution of hypercalcemia. The postoperative course was uneventful. Histopathological and immunohistochemical analyses were consistent with parathyroid adenoma. The diagnostic approach to hypercalcemia in pregnancy represents a challenge for multidisciplinary teamwork.

Keywords: Neuroendocrine tumor; Primary hyperparathyroidism; Hypercalcemia; Parathyroidectomy; Pregnancy

Introduction

Endocrine disorders in pregnancy are challenging as regards diagnosis and treatment. Primary hyperparathyroidism (PHP) is the third most common endocrine disorder, often asymptomatic. We report the management of a symptomatic case during pregnancy.

Case Report

In April 2019 (April 27), a 28-year-old woman gravida 3/para 1 at 11 weeks of gestation with no previous known diseases, presented to the Obstetrics Department of the University Hospital of Brescia, Italy, with symptoms of general weakness, hyperemesis gravidarum and hypercalcemia. There was no family history of parathyroid disease, hypercalcemia, nephrolithiasis, or other endocrinopathies. At admission the physical examination revealed tachycardia, and serum calcium was 12.2 mg/dL. Thyroid ultrasound revealed an heterogeneous mass along the inferior margin of the left thyroid gland, measuring 8 mm. Laboratory investigations included total calcium level 11.95 mg/dL (normal range, 8.10 - 9.80), parathyroid hormone (PTH) 142 pg/mL (normal range, 11 - 67), phosphorus 1.8 mg/dL (normal range, 2.5 - 4.3), serum albumin 4.02 g/dL (normal range, 3.40 - 4.65), thyroid stimulating hormone (TSH) 0.083 mU/L (normal range, 0.270 - 4.200) and fT4 22.80 (normal range, 9.30 - 17.00). Biochemical hyperthyroidism was interpreted as consistent with pregnancy-induced rise of beta human chorionic gonadotropin. A fine needle aspiration from the mass demonstrated scant cells, and it was reported as benign cytology. She was diagnosed with PHP. Conservative treatment with intravenous fluid (lactated ringers 500 mL/day and normal saline 1,000 mL/day) and furosemide 20 mg/die was started, monitoring blood pressure, daily diuresis and body weight. Meanwhile obstetric evaluation showed appropriate for gestational age fetal biometry. Neck computed tomography 4D showed a solitary adenoma of the parathyroid gland, measuring 6 × 2.9 × 11 mm (Fig. 1).

On May 15 (14 weeks of gestation), the patient underwent cervical exploration with left superior parathyroidectomy. The histopathology showed a benign adenoma (Fig. 2). The basal level of PTH was 151 pg/mL, within 10 min after the parathyroid adenoma was removed the PTH level decreased to 12 pg/mL. Intravenous glucose solution 5% (500 mL) with calcium gluconate 10% was started in the first 36 h after surgery and then was continued with oral calcium 1,000 mg two times a day. Total calcium level at the end of the intravenous calcium infusion was 8.88 mg/dL. Vitamin D supplementation (25,000 IU/week) for 6 weeks (and then one time a month) was also started and continued for 6 weeks. The postoperative period was uneventful; in particular she did not develop hypocalcemia after surgery. Her serum calcium and PTH levels normalized; on May 22, PTH was 31 pg/mL and total calcium level 8.99 mg/dL. She was discharged on May 30.

In subsequent weekly follow-up, her serum calcium and PTH levels have been within the normal limits. On October 30, at 38 weeks of gestation, the patient gave birth to a healthy female baby of adequate weight. Ethical approval was not required based on national laws regarding anonymized data.
Worldwide, PHP (overproduction of PTH due to parathyroid hyperplasia, adenoma or carcinoma) is the third most common endocrine disorder, after diabetes and thyroid disease; and women are twice as likely to be affected as men [1]. Symptoms of hypercalcemia occur in 20% of patients and include fatigue, nausea, constipation, depression, renal impairment and cardiac arrhythmias. Its occurrence during pregnancy is rare with a reported incidence of 1%, usually due to a parathyroid adenoma, which is present in approximately 80% of all cases, and often remains undiagnosed due to physiological changes during pregnancy that mask the symptoms (e.g. hypoalbuminemia, calcium transport across the placenta, increased glomerular filtration rate, estrogenic inhibition of PTH-mediated bone resorption). It is considered that as many as 80% of cases of PHP during pregnancy may be asymptomatic. However, untreated PHP can be associated with serious maternal (e.g. hypercalcemic crisis, pancreatitis, nephrolithiasis, preeclampsia) and fetal (e.g. neonatal tetany, hypoparathyroidism, stillbirth, intrauterine growth restriction, preterm delivery, and miscarriage) complications which may be as high as 67% and 80% respectively, directly proportionate to degree of maternal serum calcium levels. Because neonatal mortality is associated with maternal hyperparathyroidism, early diagnosis is essential.

The optimal management should be individualized according to the clinical course, gestational age, the severity of hypercalcemia and the risk for each treatment option for the mother and the baby. In asymptomatic patients with mild hypercalcemia (< 11 mg/dL), conservative treatment with oral hydration and low-calcium diet, with or without forced diuresis with a low dose of loop diuretic can produce good outcomes for both the mother and the baby [2]. Most clinical studies and guidelines recommend parathyroidectomy as the treatment of choice for PHP occurring in pregnancy, and it seems to be the safest beyond the second trimester [3, 4].

Acknowledgments

None to declare.
Financial Disclosure

None to declare.

Conflict of Interest

All authors have nothing to declare.

Informed Consent

The patient gave her informed consent.

Author Contributions

CZ and RO wrote the paper. SZ, C. Cappelli, C. Casella, CB and ES revised the paper as regards their specialty.

Data Availability

Any inquiries regarding supporting data availability of this study should be directed to the corresponding author.

References

1. Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, Haigh PI, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122-1129.
2. Diaz-Soto G, Linglart A, Senat MV, Kamenicky P, Chanson P. Primary hyperparathyroidism in pregnancy. Endocrine. 2013;44(3):591-597.
3. Schnatz PF, Curry SL. Primary hyperparathyroidism in pregnancy: evidence-based management. Obstet Gynecol Surv. 2002;57(6):365-376.
4. Kelly TR. Primary hyperparathyroidism during pregnancy. Surgery. 1991;110(6):1028-1033; discussion 1033-1024.